Novartis Announces Tabrecta^® First Published Overall Survival and Updated Overall Response Data in Patients with METex14 Metastatic NSCLC

Novartis AG has announced the first published mature overall survival and updated overall response rate data following treatment with Tabrecta® in adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to MET exon 14 skipping (METex14).